One of the governor’s goals related to public safety is the Department of Corrections will reduce its state correction population by 5% by 2020. DOC overall total population directly drives the Department’s budget. The baseline for the goal is the total population on June 30, 2015. On June 30, 2015, the Pennsylvania Department of Corrections overall population was 50,366.

This dataset contains the total number of state corrections population in the Department’s custody at the end of each month, including those in prison, in contracted county jails, in community phases of the State Intermediate Punishment (SIP) program, in Parole Violator Centers (PVCs), and on temporary transfer to other jurisdictions.

DOC publishes a Monthly Population Report to the DOC Website (www.cor.pa.gov). The information published to the website includes the data set and breakdown of populations in each institution.

This dataset contains summary information on opioid drug seizures and arrests made by Pennsylvania State Police (PSP) personnel, stationed statewide, on a quarterly basis. Every effort is made to collect and record all opioid drug seizures and arrests however, the information provided may not represent the totality of all seizures and opioid arrests made by PSP personnel.
Data is currently available from January 1, 2013 through March 31, 2019.
Seizure
Opioids seized as a result of undercover buys, search warrants, traffic stops and other investigative encounters.
An incident is a Pennsylvania State Police (PSP) recorded violation of the Controlled Substance Act and an entry into the PSP Statistical Narcotics System.
By regulation, entry is made by the PSP as stated in PSP Administrative Regulation 9-6:
When violations of The Controlled Substance, Drug, Device and Cosmetic Act are reported, the required statistical information concerning the incident shall be entered into the Statistical Narcotic Reporting System (SNRS).
Incidents may include undercover buys, search warrants, traffic stops and other investigative encounters
So, an “incident” is not based on any arrest, but on a reported violation, though it often can include arrests.
The incidents that are selected and forwarded to the portal are those that include a record of one or more seizures of the opioid drugs. In turn, a subset of those selected incidents also contains a record of one or more arrests.
This is PSP data only, it would not include any Federal case/incident data.

View quarterly trends in Risky Prescribing Measures, including:
o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the location of the prescriber seen by a patient meeting these criteria.
o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the individual’s county of residence.
o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions per 1,000 Population: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence.
Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/PDMPDataTechnicalNotes.pdf
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

Other Opioid related diseases page

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/PDMPDataTechnicalNotes.pdf
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

Learn page

Percent of Pennsylvania maternal hospital stays, categorized by the presence or absence of opioid use, with Medicaid as the primary payer as listed in the hospital record.

Maternal stays include those involving a delivery, as well as other pregnancy-related stays. Opioid use, or opioid use disorder, is a diagnosis indicating opioid dependence, abuse, or use. Some opioid drugs may be prescribed as part of medication-assisted treatment to relieve withdrawal symptoms and psychological cravings often associated with opioid use disorders. Opioid use during pregnancy can lead to Neonatal Abstinence Syndrome (NAS) for newborns.

This analysis is restricted to maternal hospital stays with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.

PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

Statewide rates of maternal hospital stays with opioid use per 1,000 maternal stays.

Maternal stays include those involving a delivery, as well as other pregnancy-related stays. Opioid use, or opioid use disorder, is a diagnosis indicating opioid dependence, abuse, or use. Some opioid drugs may be prescribed as part of medication-assisted treatment to relieve withdrawal symptoms and psychological cravings often associated with opioid use disorders. Opioid use during pregnancy can lead to Neonatal Abstinence Syndrome (NAS) for newborns.

This analysis is restricted to maternal hospital stays for Pennsylvania-state residents who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.

PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.